Driving Precision Oncology Through Data and Collaboration
Cancer incidence continues to rise globally, with over 2 million new cases and 600,000 deaths projected in the US in 2026, despite advances in precision oncology. Strong partnerships between researchers, industry, and clinicians are needed to address challenges and accelerate development of targeted treatments.
Cancer research has made significant progress in recent decades, enabling earlier detection and more effective treatments. However, cancer incidence continues to rise globally, driven by population growth and aging. In the US, over 2 million new cancer cases and 600,000 deaths are projected in 2026. Precision oncology has transformed cancer research, but achieving consistency and scalability remains a challenge due to high costs, limited access to diagnostic tests, and complex regulatory frameworks. Addressing these challenges requires strong partnerships between researchers, industry, clinicians, regulators, and patient communities to prioritize unmet needs and accelerate development. The American Association for Cancer Research Annual Meeting 2026 emphasized the importance of precision, partnership, and purpose in advancing cancer science.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.